Archive: Company News
ImmunOs Therapeutics Appoints Dr. Hilmar Ebersbach as Vice President Antibody Development and Protein Engineering
– Former Novartis director brings significant expertise in drug discovery and development
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the appointment of Dr. Hilmar Ebersbach as Vice President Antibody Development and Protein Engineering (ADPE).
InfanDx AG Reports Successful Validation of Biomarker Panels for the Early Detection of Hypoxic Ischemic Encephalopathy
— Numerous metabolic biomarkers identified in AAMBI study confirmed in BANON cohort
— Panel sensitivities of up to 89% at specificities of up to 93% in blinded validation study
— Formal IVD development of HypoxE® Test progressing on schedule
InfanDx AG, a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced that it successfully completed the validation of metabolic biomarker panels for the early detection of Hypoxic Ischemic Encephalopathy (HIE) in newborns. The validated biomarkers of such panels will be the target of the Company’s HypoxE® blood test for the early detection of HIE.
ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors
– Seasoned immuno-oncology executive brings significant medical and biopharma expertise
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that Joseph Leveque, MD, has been appointed to the Company´s Board of Directors.
TolerogenixX Publishes Three-Year Follow-Up Data from Phase I Trial of Immune Tolerance-Inducing MIC-Lx Cell Therapy
— Publication in high-impact Journal of the American Society of Nephrology
— Results pave the way for a novel cell therapy in organ transplantation
TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, today announced 3-year follow-up data of a Phase I trial of its MIC-Lx cell therapy. The results published ahead of print in the Journal of the American Society of Nephrology (doi: 10.1681/ASN.2022020210) indicate that donor-specific immunosuppression after MIC infusion is long-lasting and associated with a striking increase in regulatory B lymphocytes.